Tagged: immunology
30 results
Daniel Getts
Daniel Getts, PhD, is the co-founder and CEO of CREATE Medicines (formerly Myeloid Therapeutics), a Cambridge, Massachusetts biotech building RNA-based in vivo immune programming therapies that reprogram T cells, NK cells and myeloid cells directly inside the body. An immunologist trained at the University of Sydney with an MBA from Western Michigan, he previously founded Cour Pharmaceuticals and served as VP of Research at TCR2 Therapeutics. He has more than 45 peer-reviewed publications, multiple issued patents, and a track record of large pharma partnerships, including Takeda's $420M licensing deal for TIMP-GLIA. In May 2026 CREATE closed a $122 million Series B to advance its in vivo CAR pipeline across autoimmune disease and oncology.
Merida Biosciences
Merida Biosciences is a Cambridge, Massachusetts biotechnology company developing a new class of engineered Fc biotherapeutics that selectively bind and eliminate the disease-causing antibodies behind autoimmune and allergic diseases, while sparing the protective antibodies the immune system needs. Launched publicly in April 2025 with a $121 million Series A, the company aims to treat conditions such as Graves' disease, IgE-mediated allergy and primary membranous nephropathy by clearing pathogenic antibodies and suppressing the B cells that make them - without the broad immunosuppression that limits many existing therapies.
NextRNA Therapeutics
NextRNA Therapeutics was a Boston-based biotechnology company pioneering small-molecule drugs that target long non-coding RNAs (lncRNAs) - a vast, largely undrugged region of the genome that regulates gene expression. Built on the science of Dana-Farber's Carl Novina and led by co-founder and CEO Dominique Verhelle, the company developed a proprietary discovery engine to map disease-relevant lncRNA-protein interactions and drug them with selective small molecules across oncology and immunology. NextRNA raised roughly $56 million in seed and Series A financing and signed a collaboration with Bayer worth up to $547 million before winding down operations in August 2025 amid a difficult biotech market and a missed partnership milestone.
Paratus Sciences
Paratus Sciences is a biotechnology company decoding the extreme biology of bats to discover first-in-class medicines. Bats live long, tolerate viruses, resist cancer, control inflammation and thrive on high-sugar diets - traits they evolved over roughly 65 million years. Paratus integrates cell biology, comparative genomics and informatics to translate these adaptations into drug targets for inflammatory and cardiometabolic diseases. Launched in 2023 with a $100M Series A and dual sites in New York and Singapore, its lead program PS-1001 is a first-in-class pan-inflammasome inhibitor.
Prolium Bioscience
Prolium Bioscience is a New York-based, clinical-stage biotechnology company developing PRO-203, a bispecific CD20xCD3 T-cell engager designed to deplete disease-driving B cells as an off-the-shelf therapy for severe autoimmune diseases, starting with systemic sclerosis and lupus. Founded in 2025 and backed by RTW Investments, the company in-licensed global non-oncology and ex-Asia oncology rights to the antibody from China's InnoCare Pharma and KeyMed Biosciences, and launched publicly in March 2026 with a $50 million Series A alongside first-patient dosing.
Rapafusyn Pharmaceuticals
Rapafusyn Pharmaceuticals is a Baltimore-based, clinical-stage drug discovery company spun out of Johns Hopkins University. Its RapaGlue platform designs non-degrading, cell-permeable macrocyclic molecular glues that modulate hard-to-drug intracellular and transmembrane targets - drawing on a proprietary DNA-encoded library of more than 8 billion compounds and machine learning for target selection. The lead program, RAP-0001, is a selective ENT1 inhibitor advancing toward IND-enabling studies for the prevention of acute kidney injury in cardiac surgery patients, with a broader pipeline spanning oncology, immunology, and pain.
SEED Therapeutics
SEED Therapeutics is a clinical-stage biotechnology company pioneering rationally designed molecular glue degraders to treat diseases driven by proteins long considered undruggable. Powered by its proprietary RITE3 discovery platform - which pairs disease-causing target proteins with the most suitable of more than 600 human E3 ligases - SEED reprograms the cell's own ubiquitin-proteasome system to destroy harmful proteins rather than merely block them. Founded in 2020 by CEO Lan Huang and a group of protein-degradation pioneers including Nobel laureate Avram Hershko, the company advanced its lead oral RBM39 degrader ST-01156 into first-in-human Phase 1 trials in early 2026, with a broader pipeline spanning oncology, neurodegeneration, immunology and virology backed by partners Eli Lilly and Eisai.
Stablix, Inc.
Stablix, Inc. is a preclinical biopharmaceutical company pioneering targeted protein stabilization (TPS), a new therapeutic modality that does the opposite of protein degraders. Its RESTORE platform generates heterobifunctional small molecules called RESTORACs that recruit deubiquitinase enzymes (DUBs) to selectively remove ubiquitin from disease-relevant proteins, restoring deficient proteins to therapeutic levels or correcting aberrant protein function. Co-located in New York City and Boston and founded on science from Columbia University, Stablix has raised roughly $78M and is developing programs in cancer, rare diseases and immunological disorders, including a strategic collaboration with Vertex Pharmaceuticals.
Eddine Saiah
Eddine Saiah, Ph.D., is the CEO and President of Stablix, a preclinical biotechnology company pioneering targeted protein stabilization (TPS) as a new class of small-molecule medicines. A medicinal chemist and drug hunter with more than 25 years of experience, he joined Stablix as Chief Scientific Officer in 2022 and moved into the chief executive role in 2025. His career spans big pharma research leadership at Pfizer and Wyeth, an entrepreneur-in-residence stint at Atlas Venture, and CSO duties at Navitor Pharmaceuticals. He is a co-inventor and author on more than 120 patents and publications, and has helped advance more than a dozen small-molecule candidates into clinical trials.
Enveda
Enveda is a clinical-stage biotech that uses artificial intelligence to read the chemistry of the natural world and turn it into new medicines. Founded in 2019 by Viswa Colluru, the company built PRISM, a foundation model trained on more than a billion mass spectra, to decode the structure of natural molecules that traditional methods leave invisible. That platform has produced a pipeline of small-molecule drug candidates - led by ENV-294, an oral anti-inflammatory now in Phase 2 trials for atopic dermatitis and asthma. Backed by more than $700M in funding and valued as a unicorn, Enveda operates out of Boulder, Colorado and Hyderabad, India.
IgGenix, Inc.
IgGenix is a clinical-stage biotechnology company in South San Francisco developing fully human, allergen-specific antibody therapeutics for severe food and environmental allergies. Its proprietary SEQ SIFTER single-cell RNA-sequencing platform isolates the rare IgE-producing B cells behind allergic reactions and re-engineers them into protective IgG antibodies designed to block the allergic cascade. The lead candidate, IGNX001, is in a Phase 1 trial for peanut allergy.
Nuvig Therapeutics
Nuvig Therapeutics is a clinical-stage biotech in the San Francisco Bay Area developing next-generation immune modulators for chronic autoimmune and inflammatory diseases. Founded in 2022 on research from The Rockefeller University, its lead candidate NVG-2089 is a first-in-class recombinant Fc fragment that engages type II Fc receptors to recapitulate the anti-inflammatory benefits of IVIg without immunosuppression or the supply constraints of plasma-derived products. The company raised a $161M Series B in December 2024 to push NVG-2089 into Phase 2 for CIDP and other indications.
Tony Kingsley
Tony Kingsley is a biopharmaceutical executive who runs Stablix, Inc., a New York biotech betting that you can treat disease by protecting proteins instead of destroying them. He took the CEO seat in February 2022 after a career of running one drug company after another - Scholar Rock, TARIS Bio, The Medicines Company - and heading global commercial at Biogen, with a McKinsey partnership and a stint in medical devices before that. In July 2025 he joined the board of Indivior. He holds a Dartmouth degree and a Harvard MBA.
Fortitude Biomedicines
Fortitude Biomedicines is a Waltham, Massachusetts biotech that launched in early 2026 with $13M in seed financing to develop next-generation antibody-based therapies for autoimmune diseases and cancer. Its proprietary GLUE-DAC platform bolts molecular glue degraders onto antibody-drug conjugates, aiming to use catalytic targeted protein degradation to widen the therapeutic window of ADCs and overcome the resistance that has dogged the field. Its lead program, FORT-202, is a first-in-class T-cell targeting bispecific antibody for axial spondyloarthritis expected to reach the clinic in the first half of 2027.
Primal Health
Primal Health is a Minneapolis-based molecular biotechnology company reinventing oral care by rebalancing the microbiome instead of nuking it. Founded by Berkeley-trained microbiologist Dr. Emily Stein, the company uses its patented SMMRT (Selective Microbial Metabolism Regulation Technology) to put harmful mouth bacteria on a 'keto diet' - blocking their ability to feed on sugars while feeding the beneficial ones. Its two brands, Daily Dental Care for people and TEEF for Life for pets, deliver clinically studied lozenges and prebiotic powders that support gum health, fresher breath and a healthier oral ecosystem for humans and animals alike.
Allison Luo
Allison Luo, MD is the Chief Medical Officer of Mirador Therapeutics, a San Diego precision-medicine company that launched in 2024 with more than $400 million to attack immuno-fibrotic diseases using its Mirador360 development engine. A physician scientist with more than two decades in clinical development, she was CMO of Prometheus Biosciences before Merck bought it for $10.8 billion, and has since reassembled with that team to build Mirador. She sits on the board of Triveni Bio and has held medical-leadership roles across Ventyx, Biora, Iveric Bio and Bristol Myers Squibb.
AltruBio Inc.
AltruBio is a clinical-stage San Francisco biotech developing first-in-class immune checkpoint enhancer antibodies for autoimmune and inflammatory diseases. Its lead program, ALTB-268, targets PSGL-1 to restore T-cell homeostasis, and is advancing through mid-stage trials in ulcerative colitis. The company rebranded from AbGenomics in 2020 under CEO Judy Chou and closed an oversubscribed $225M Series B in 2024.
EpiBiologics
EpiBiologics is a San Mateo biotech building bispecific antibodies that grab disease-driving proteins on the outside of cells and drag them into the trash. Its EpiTAC platform - spun out of Jim Wells' lab at UCSF - taps a library of more than 270 internalizing receptors so degradation happens in the right tissue and nowhere else. With $280M raised across Seed, Series A and a 2026 Series B led by GV and Johnson & Johnson, the company has pushed its lead EGFR degrader, EPI-326, into a Phase 1 trial for lung and head-and-neck cancers.
Kimia Therapeutics
Kimia Therapeutics is a Berkeley-based biotech building ATLAS, a drug-discovery platform that pairs nanoliter-scale high-throughput precision chemistry with machine learning and genome editing to map the druggable space at single-atom resolution. Spun out of Carmot Therapeutics in 2023 and backed by $55M in Series A funding, Kimia is using its chemical atlas to advance therapeutic programs in cancer and immunology.
Emily Stein
Emily Stein is a microbiologist turned founder and CEO of Primal Health, the Minneapolis life-sciences company behind Daily Dental Care for people and TEEF for Life for pets. Trained at UC Berkeley and Stanford, she spent more than a decade building SMMRT (Selective Microbial Metabolism Regulation Technology), a 'carrot and stick' approach that starves harmful mouth bacteria and feeds the helpful ones instead of nuking everything. Holder of 18 patents and a five-time startup founder, Stein pivoted from humans to dogs when dentists balked, a move she says saved the company. Her stated goal: to be in every mouth at least once a day.
Protagonist Therapeutics
Protagonist Therapeutics is a Newark, California clinical-stage biopharmaceutical company that turns peptides - short chains of amino acids long dismissed as too fragile to be drugs - into stable, often orally available medicines. Its proprietary peptide discovery and engineering platform powers a pipeline spanning hematology, inflammation/immunology and metabolic disease, anchored by rusfertide (a hepcidin mimetic for polycythemia vera under FDA Priority Review) and icotrokinra, an oral IL-23 receptor blocker partnered with Johnson & Johnson that reached the U.S. market in 2026. Publicly traded on Nasdaq as PTGX, the company pairs internal discovery with high-value pharma partnerships.
Aditya Venugopal
Aditya Venugopal is the Chief Business Officer of Alentis Therapeutics, a clinical-stage Swiss biotech chasing first-in-class therapies aimed at claudin-1 for fibrosis and cancer. An immunologist turned dealmaker, he spent 15-plus years moving between the lab bench and the negotiating table: a Ph.D. in immunology from Weill Cornell, seven years in strategic life-science consulting, then senior roles at Intercept, VectivBio and Versanis Bio. He has a habit of being in the room when companies get acquired - VectivBio went to Ironwood, Versanis went to Eli Lilly - and he reunited with CEO Mark Pruzanski at Alentis after first partnering with him at Intercept.
Arda Therapeutics
Arda Therapeutics is a San Carlos, California biotech building precision biologics that eliminate the specific cells driving chronic disease rather than tinkering with the proteins those cells produce. Using a single-cell data discovery engine, Arda maps disease-specific cell states, pinpoints their surface markers, and designs targeted therapies that deplete only the harmful cells while sparing healthy tissue. Founded in 2021 by former Calico scientist Adam Freund, the company is applying lessons from oncology to fibrosis, autoimmune, and metabolic disease, backed by a $43M Series A led by a16z Bio + Health.
ArkeaBio
ArkeaBio is a Boston climate-biotech company building the first vaccine that cuts methane emissions from cattle. The shot trains a cow's immune system to produce antibodies that travel to the rumen and suppress methanogens - the microbes that turn digestion into greenhouse gas. Livestock methane accounts for roughly 6% of global emissions, and ArkeaBio's pitch is blunt: a vaccine is the lowest-cost, most scalable way to attack that number. Backed by Breakthrough Energy Ventures and a roster of climate and ag investors, the company is moving from animal studies into full field trials, targeting a 20% methane reduction and a first product in market around 2028.
DeepCure
DeepCure is a Boston-based biotech that uses AI, physics-based simulation, and automated robotic chemistry to design novel small-molecule drugs for hard-to-treat immune and inflammatory diseases. Founded in 2018 by MIT Media Lab researchers, the company pairs deep learning with a proprietary chemical database of up to 10^18 synthesizable compounds and an in-house automated wet lab, aiming to turn AI-generated molecules into real, testable, first-in-class therapies.
Gate Bioscience
Gate Bioscience is a Brisbane, California biotech building a brand-new class of medicines it calls Molecular Gates: oral small molecules that stop disease-causing proteins from ever leaving the cell. Instead of chasing proteins after they are secreted into the body, Gate's drugs bind Sec61, the single channel every one of the roughly 4,000 human secreted and membrane proteins must pass through, and selectively block a target protein so the cell degrades it. Founded in 2021 and emerged from stealth in 2023 with $60M, the company has raised about $135M total and is pushing its lead programs toward IND-enabling studies and Phase 1 trials.
GentiBio
GentiBio is a clinical-stage biotechnology company in Cambridge, Massachusetts building engineered regulatory T cell (EngTreg) therapies designed to restore immune tolerance and durably treat autoimmune, autoinflammatory, alloimmune, and allergic diseases. Spun out of research from Seattle Children's, Benaroya Research Institute, and MIGAL Galilee Research Institute, the company combines gene editing of FOXP3 with a modular Treg engineering and manufacturing platform. Its lead program, GNTI-122, is an autologous antigen-specific Treg therapy for recently diagnosed type 1 diabetes now in a Phase 1 trial (POLARIS). GentiBio has raised roughly $177M and signed a partnership with Bristol Myers Squibb worth up to $1.9B in potential milestones.
Immetas Therapeutics
Immetas Therapeutics is a New Jersey biotech building drugs that target the chronic, low-grade inflammation that drives aging and age-related disease - what scientists call 'inflammaging.' Founded in 2018 by drug-development veteran J. Gene Wang and Harvard aging researcher David Sinclair, the company designs bispecific antibodies and other biologics to reprogram the innate immune system, aiming to treat age-related cancers and inflammatory and autoimmune disease. It raised an $11M Series A from Morningside Ventures in 2020 and partners with GC Biopharma on mRNA therapeutics.
Kira Biotech Pty Ltd
Kira Biotech is a Brisbane-based clinical-stage immunology company developing first-in-class antibody therapeutics that retrain the immune system instead of broadly suppressing it. Its lead candidate, KB312, selectively depletes activated immune cells to restore immune tolerance, aiming to treat difficult autoimmune and inflammatory conditions such as rheumatoid arthritis, lupus, type 1 diabetes, and graft-versus-host disease. Built on decades of dendritic-cell research from Australian institutes and led by US rheumatologist Dr Dan Baker, the company launched with a A$20 million Series A in 2019 led by OneVentures and IP Group.
Alexey Lugovskoy
Alexey 'Alex' Lugovskoy is the co-founder and CEO of Diagonal Therapeutics, a Watertown/Cambridge, Massachusetts biotech building 'clustering' antibodies that switch cellular signaling back on rather than block it. A Harvard-trained biophysicist who left physics after deciding green leaves were more interesting than tau neutrinos, he spent two decades in antibody R&D at Biogen, Merrimack, Morphic, and Dragonfly before launching Diagonal in 2022. He has co-invented an FDA-approved cancer drug, authored more than 100 patents and papers, and edits the antibody journal mAbs. In January 2026 Diagonal closed an oversubscribed $125M Series B co-led by Sanofi Ventures and Janus Henderson to push its lead program, DIAG723, into human trials for hereditary hemorrhagic telangiectasia.